Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
US5861161A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Sep 7, 1994 |
| Grant date | Jan 19, 1999 |
| Priority date | — |
| Expiry date | Sep 7, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2810/6054
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed toward chimeric human immunodeficiency virus type 1 and 2 (HIV-1 and -2) proteins that are capable of being incorporated into the virion when expressed in trans. These chimeric proteins consist of a first portion comprising an HIV-1 or HIV-2 Vpr/Vpx virion incorporation domain which includes the predicted N-terminal alpha helix. This domain is capable of interacting with the p6 domain of the Pr55.sup.gag. The second portion of the chimera comprises a sequence containing RNase activity, protease activity, or a domain capable of inhibiting virion morphogenesis and assembly. The disclosed invention provides a chimera that affects the structural organization or functional integrity of the mature virion by enzymatic disturbance or steric hindrance of the virion.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.